'Sunifiram (DM-235) je ampakinski lek koji deluje kao pozitivni alosterni modulator AMPA receptora,[4] i pokazuje nootropne efekte u životinjskim ispitivanjima sa znatno većom potentnošću od piracetama.[5][6]
Kratke činjenice (IUPAC) ime, Klinički podaci ...
Zatvori
Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit Galeotti, N.; Ghelardini, C.; Pittaluga, A.; Pugliese, A.; Bartolini, A.; Manetti, D.; Romanelli, M.; Gualtieri, F. (2003). „AMPA-receptor activation is involved in the antiamnesic effect of DM 232 (unifiram) and DM 235 (sunifiram)”. Naunyn-Schmiedeberg's archives of pharmacology 368 (6): 538–545. DOI:10.1007/s00210-003-0812-6. PMID 14600801. Ghelardini, C.; Galeotti, N.; Gualtieri, F.; Romanelli, M.; Bucherelli, C.; Baldi, E.; Bartolini, A. (2002). „DM235 (sunifiram): a novel nootropic with potential as a cognitive enhancer”. Naunyn-Schmiedeberg's archives of pharmacology 365 (6): 419–426. DOI:10.1007/s00210-002-0577-3. PMID 12070754. Romanelli, M.; Galeotti, N.; Ghelardini, C.; Manetti, D.; Martini, E.; Gualtieri, F. (2006). „Pharmacological characterization of DM232 (unifiram) and DM235 (sunifiram), new potent cognition enhancers”. CNS Drug Reviews 12 (1): 39–52. DOI:10.1111/j.1527-3458.2006.00039.x. PMID 16834757.
|
Portal Medicina |
|
Portal Hemija |